Jefferies slashes HCA target

Jefferies analyst Brian Tanquilut has taken his price target for shares of HCA Holdings from $112 all the way down to $88 after the hospital giant previewed its third-quarter profits and said its personnel costs had risen over the summer. Tanquilut also has trimmed his earnings estimates for this year and next. But he is sticking to his 'buy' rating and says HCA can continue to grow its business.

At about 12:30 p.m., HCA shares (Ticker: HCA) were off more than 6 percent to about $71.20. They're now down slightly year to date.

Oct 15, 2015 12:52 PM

Surgery Partners adds debt capacity

Expansion with new lenders come shortly after so-so IPO
Oct 12, 2015 7:14 AM

Jefferies sees 20%+ rise in Acadia

Analyst Brian Tanquilut at Jefferies & Co. sees many bright days ahead for Acadia Healthcare investors. Following the company's second-quarter earnings report, he has raised his price target for the stock to $100 from $88. That leaves a lot of upside: Acadia (Ticker: ACHC) closed last week's trading at $81.02 and is to $81.84 this afternoon.

Aug 17, 2015 2:13 PM

Jefferies trims Genesco target

Jefferies analyst Edward Plank has reiterated his 'hold' rating on shares of Genesco after the retailer's first-quarter earnings report. But Plank also his trimmed his price target for the Nashville-based seller of shoes and hats to $67 from $69. Genesco (Ticker: GCO) closed Monday's session at $65.27 and is down 15 percent so far this year.

Jun 2, 2015 8:41 AM

Analysts hike Acadia targets

This post has been updated to correct the info on Deutsche's call

Several investment firms tracking Acadia Healthcare on Thursday updated their models for the Franklin-based operator of behavioral health facilities after its Q1 report, which included word of three acquisitions in the United Kingdom. Analysts at Jefferies have hiked their price target to $88 from $76 while their peers at Cantor Fitzgerald now see Acadia climbing to $84 instead of $70. And Wells Fargo researchers have upgraded the stock to 'outperform' from 'market perform.'

Not everyone is quite that upbeat, though: At Deutsche Securities, veteran analyst Darren Lehrich has reiterated his 'buy' rating, saying he expects more acquisitions this year. But he has raised his target to "only" $77 from $72.

Investors appear to be paying more attention to Lehrich's move than to the more positive takes. At about 1:15 p.m., Acadia shares (Ticker: ACHC) were down slightly to $68.61 on volume that already had topped the daily average. So far this year, they've risen about 12 percent.

Apr 30, 2015 1:33 PM

Jefferies starts coverage on AmSurg

Analysts at Jeffries Group have begun coverage on Nashville-based AmSurg. Starting last week, the firm gave the ambulatory surgery company a 'buy' rating and a price target of $65. Shares of AmSurg (Ticker: AMSG) closed down about 2 percent at $55.34 Monday. In the last six months, they're up 12 percent.

Feb 10, 2015 8:15 AM

Report: American HomePatient pursuing sale

Company owned by Dallas investors retains Jefferies
Dec 11, 2014 7:09 AM

Jefferies: 2,200 is more likely FTC Dollar General divestiture target

Jefferies analyst Daniel Binder isn't buying the idea that Dollar General might be forced to sell off 4,000 stores should it succeed in buying Family Dollar. Yes, it's possible the Federal Trade Commission is driving at a hard bargain, Binder said in a Wednesday note to clients, but he expects the divestiture requirement will be around 2,200 instead of the much larger number sources passed on to the New York Post earlier this week.

"Even if we removed Walmart from our own market analysis, we get to about 2,900 stores that the FTC could take issue with," Binder wrote, adding that it "seems like more than a coincidence" that the New York report came hours before Family Dollar and Dollar Tree said they were pushing back the date of their merger vote.

Investors appear to have largely digested — if not altogether dismissed — the 4,000-store report. At about 1:40 p.m. Thursday, shares of Dollar General (Ticker: DG) were up about 1 percent on the day — and up about the same from their Tuesday close — and changing hands at $66.72.

Nov 20, 2014 1:42 PM

Analyst action: Delek, Brookdale, Genesco

Cowen & Co. analyst Sam Margolin has turned more bullish on Delek US Holdings, hiking his rating to 'outperform' from 'market perform' and lifting his price target to $43 from $32. Among his reasons for optimism are better numbers from Delek's Arkansas and Texas refineries as well as greater contributions from its Delek Logistics affiliate and a stronger cash position. Delek shares (Ticker: DK) are up 3 percent to about $33.60 today and have climbed 17 percent in the past five sessions.

At Stifel Nicolaus, analyst Dan Bernstein has reiterated his buy on shares of Brookdale Senior Living and hiked his price target to $40 from $38. Brookdale shares (Ticker: BKD) are changing hands around $33.35.

Edward Plank at Jefferies & Co. has begun covering shares of shoe and hat retailer Genesco with a 'hold' rating and little expectation that the company's shares (Ticker: GCO) will go anywhere in the next couple of quarters. Plank's price target for Nashville-based Genesco is $82, barely a buck above where the shares have traded over the past few days.

Aug 11, 2014 2:20 PM

Analyst: HCA's Q2 could lead to 'stock-enhancing capital deployment'

Jefferies & Co. analyst Brian Tanquilut sees bigger things coming from HCA Holdings' positive earnings preview this week. He thinks that "HCA's strong cash flows open up opportunities for stock-enhancing capital deployment" such as acquisitions or share buybacks. (The company late last year spent $500 million to repurchase some of its stock.) Tanquilut also lifted his price target for HCA to $72 from $70.

Jul 18, 2014 6:47 AM